Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...

AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company ...

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...